 |
| Anno I | Numero 7 | Novembre 2016 |
| Comitato scientifico editoriale: Sergio Bracarda, Giacomo Cartenì, Giuseppe Procopio Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential |
| Clear cell renal cell carcinoma (ccRCC) is an aggressive tumor that is characterized in most cases by inactivation of the tumor suppressor gene VHL. The VHL/HIF/VEGF pathway thus plays a major role in angiogenesis and is currently targeted by anti-angiogenic therapy. The emergence of resistance is leading to the use of targeted immunotherapy against immune checkpoint PD1/PDL1 that restores antitumor immune response. The correlation between VHL status and PD-L1 expression has been … |
| Continua a leggere |
| Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy |
| Survival of patients with metastatic renal cell carcinoma (mRCC) has improved since the advent of targeted therapy. Approved agents include the multi-targeted tyrosine kinase inhibitors (TKIs) sunitinib, sorafenib, axitinib, pazopanib, cabozantinib, and lenvatinib (approved in combination with everolimus), the anti-VEGF monoclonal antibody bevacizumab, the mammalian target of rapamycin (mTOR) inhibitors everolimus and temsirolimus, and the programmed death-1 (PD-1) targeted immune checkpoint … |
| Continua a leggere |
| Medical treatment of renal cancer: new horizons |
| Renal cell carcinoma (RCC) makes up 2-3% of adult cancers. The introduction of tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin inhibitors in the mid-2000s radically changed the management of RCC. These targeted treatments superseded immunotherapy with interleukin-2 and interferon. The pendulum now appears to be shifting back towards immunotherapy, with the evidence of prolonged overall survival of patients with metastatic RCC on treatment with the anti-programmed cell death 1 … |
| Continua a leggere |
| Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma |
| Emerging agents blocking the programmed cell death 1 (PD-1) pathway show activity in metastatic clear cell renal cell carcinoma (mRCC). The aim of this study was to evaluate the efficacy and safety of vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-tyrosine kinase inhibitor (TKI) therapy after PD-1 inhibition. Patients with mRCC treated with anti-PD-1 antibody (aPD-1) monotherapy or in combination (with VEGFR-TKI or ipilimumab) that subsequently received VEGFR-TKI … |
| Continua a leggere |
| Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy |
| Pembrolizumab is a monoclonal antibody that is designed against programmed cell death protein 1 (PD-1). Pembrolizumab and other immunocheckpoint-blocking monoclonal antibodies work by modulating a patient's own immune system to increase anti-tumor activity. While immunocheckpoint blockade has shown promising results, only 20-40 % of patients experience objective clinical benefit. Differences in individual tumor biology and the presence multiple immune checkpoints present a challenge for … |
| Continua a leggere |
| Appuntamenti AIOM |
| Coniugare Innovazione, Sostenibilità e Continuità di Cura in Oncologia: Il Ruolo delle Reti Regionali |
| Milano, 19 novembre 2016 |
| Le reti oncologiche regionali: dal governo clinico alla definizione del PDTA |
| Firenze, 23 novembre 2016 |
| Incontri di Aggiornamento del Dipartimento Oncologico |
| Negrar (VR), 24 e 29 novembre Negrar (VR), 7 e 13 dicembre |
| Tra clinica e ricerca in oncologia: come il laboratorio ed i risultati della ricerca entrano nei nostri ambulatori Congresso G.O.N.O. nel 29° anniversario della Fondazione |
| Pisa, 24 – 25 novembre 2016 |
| First International Congress Clinical Needs and Translational Research in Oncology |
| Reggio Emilia, 28 – 29 novembre 2016 |
| Immunotherapy Bridge 2016 |
| Napoli, 30 novembre 2016 |
| XII Congresso “Giornate Oncologiche dei Castelli Romani” |
| Frascati (RM), 2 – 3 dicembre 2016 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo di  |